Nkarta, Inc.

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the presentation of four preclinical data abstracts focused on its natural killer cell platform and pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2022.

Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at AACR Annual Meeting 2022

Appointment brings extensive operational expertise in supply chain and novel commercial-scale manufacturing systems

Nkarta Appoints Manufacturing Technology Executive, Angela Thedinga, to Board of Directors

The consensus price target hints at a 478.4% upside potential for Nkarta, Inc. (NKTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 478% Upside in Nkarta, Inc. (NKTX): Can the Stock Really Move This High?

SOUTH SAN FRANCISCO, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2021.

Nkarta Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will present four posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting to be held April 8 to 13, 2022.

Nkarta to Present Preclinical Data from Engineered NK Cell Platform at the American Association for Cancer Research 2022 Annual Meeting

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to NKX101 for treatment of acute myeloid leukemia (AML).

Nkarta Receives U.S. FDA Orphan Drug Designation for NKX101 for Treatment of Patients with AML

SOUTH SAN FRANCISCO, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today presented a trial in progress poster on NKX019 for the treatment of relapsed and refractory B-cell malignancies at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH).

Nkarta Presents NKX019 Trial in Progress Poster at the 2021 ASH Annual Meeting and Exposition

The mean of analysts' price targets for Nkarta (NKTX) points to a 270.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Can Nkarta (NKTX) Climb 270% to Reach the Level Wall Street Analysts Expect?

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the presentation of four preclinical data abstracts focused on its natural killer cell platform and pipeline at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting and Pre-Conference Programs.

Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the third quarter ended September 30, 2021.

Nkarta Reports Third Quarter 2021 Financial Results and Business Update

Nkarta Inc (NASDAQ: NKTX) has updated guidance on initial data readout of Phase 1 trial of NKX101 in relapsed or refractory acute myeloid leukemia or higher-risk myelodysplastic syndromes. Data from the engineered CAR NK cell therapy candidate targeting the NKG2D ligand is expected in 1H of 2022, against the end of 2021 expected earlier.

Nkarta Expects Initial Data From CAR NK Cell Therapy In Blood Cancer In 2022

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced NKX019 and NKX101 clinical development program updates.

Nkarta Announces Updates to NKX019 and NKX101 Clinical Development Programs

SOUTH SAN FRANCISCO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced four presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting and Pre-Conference Programs to be held November 10-14, 2021.

Nkarta to Present Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the second quarter ended June 30, 2021.

Nkarta Reports Second Quarter 2021 Financial Results and Business Progress

Nkarta Therapeutics Inc (NASDAQ: NKTX) will be moving into an 88,000-square-foot facility that will not only serve as its newest headquarters but will support the research, development, and future commercial manufacturing of its cell therapy pipeline.  The Company did not disclose the cost of the project.

Nkarta Unveils Plans For New San Francisco HQ, Manufacturing Site

SOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it has signed a lease agreement for a facility to support research and development and future commercial manufacturing of Nkarta's cell therapy pipeline. The new facility will also serve as the company's headquarters with office space and research facilities. The manufacturing center will be custom designed to complement Nkarta's state-of-the-art technology platform and optimize the production of its multiple off-the-shelf NK cell therapy investigational products. Nkarta plans to produce materials for potential pivotal clinical trials and commercial launch at the new center.

Nkarta Establishes New Combined NK Cell Therapy Manufacturing Facility / Company Headquarters

SOUTH SAN FRANCISCO, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that Chief Executive Officer Paul Hastings has been elected as the Chair of the Biotechnology Innovation Organization (BIO) Board of Directors for the 2021-2022 term.

Nkarta Therapeutics CEO, Paul Hastings, Named BIO Chair for 2021-2022 Term

CRISPR Therapeutics

Unfortunately, this isn't an endorsement by a big drug developer.

How Much Will the Nkarta Deal Help CRISPR Therapeutics?

SOUTH SAN FRANCISCO, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at this upcoming investor conference:

Nkarta Announces June 2021 Investor Conference Schedule

SOUTH SAN FRANCISCO, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the first quarter ended March 31, 2021.

Nkarta Reports First Quarter 2021 Financial Results and Business Progress

Nkarta Inc (NASDAQ: NKTX) has collaborated with CRISPR Therapeutics AG(NASDAQ: CRSP) to co-develop and commercialize two CAR-NK therapies, in addition to an NK+T program. The companies will split all the R&D costs and any worldwide profits, 50/50.

Nkarta, CRISPR Join Forces On CAR-NK Development For Cancer

The stock price of Nkarta Inc (NASDAQ: NKTX) increased by over 10% pre-market. This is why it happened.

NKTX Stock: Over 10% Increase Pre-Market Explanation

SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that the U.S. Food & Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to study NKX019 in patients with relapsed or refractory B cell malignancies.

Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell Malignancies

SOUTH SAN FRANCISCO, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2020.

Nkarta Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Business Progress

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conferences:

News for Nkarta, Inc. Stock (NKTX)